[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Anna Stanhewicz, PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":231},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,72,91,111,131,150,171,196,214],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100573679","early-phase-1-vascular-effects-of-high-salt-after-preeclampsia-100573679",false,"NCT06749418","Vascular Effects of High-Salt After Preeclampsia","Role of the Mineralocorticoid Receptor in Microvascular Endothelial Dysfunction After Preeclampsia","Inclusion Criteria:\n\n* women who had preeclampsia and women who did not have preeclampsia\n* 12 weeks to 5 years postpartum\n* 18-45 years old\n\nExclusion Criteria:\n\n* history of hypertension or metabolic disease before pregnancy\n* history of gestational diabetes\n* history of gestational hypertension without preeclampsia\n* skin diseases\n* current tobacco use\n* current antihypertensive medication\n* statin or other cholesterol-lowering medication\n* currently pregnant\n* body mass index less than 18.5 kg\u002Fm2\n* allergy to materials used during the experiment.(e.g. latex),\n* known allergy to study drugs or salt-supplement",true,"FEMALE","18 Years","45 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. Importantly, women who had preeclampsia have an exaggerated vascular responsiveness to hypertensive stimuli, such as high-salt intake, compared to women who had a healthy pregnancy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. While the association between a history of preeclampsia and vascular dysfunction leading to elevated CVD risk is well known, the mechanisms underlying this dysfunction remains unclear.\n\nThe purpose of this study is to examine the role of vascular mineralocorticoid receptor, the terminal receptor in the angiotensin system that contributes to blood pressure regulation, in mediating exaggerated microvascular endothelial dysfunction before and after a high-salt stimulus. This will help us better understand the mechanisms of microvascular dysfunction these women, and how inhibition of these receptors may improve microvascular function.\n\nIn this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickel-sized area of the skin.",[28,29],"Preeclampsia","Preeclampsia Postpartum","RECRUITING","2026-02-10",{"date":33,"type":34},"2026-02-13","ACTUAL",{"date":36,"type":34},"2025-01-02",{"date":38,"type":22},"2027-11-15",{"name":40,"class":41},"Anna Stanhewicz, PhD","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100586130","phase-1-the-impact-of-gestational-diabetes-mellitus-on-cerebral-blood-flow-and-cerebrovascular-function-after-pregnancy-100586130","NCT06911372","The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy","INCLUSION CRITERIA:\n\n* Post-partum women\n* 18 years or older\n* Delivered within 5 years from the study visit\n* History of gestational diabetes diagnosed by an obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes OR history of uncomplicated pregnancy (defined as no history of gestational diabetes, hypertensive pregnancy, or other gestational disorder).\n\nEXCLUSION CRITERIA: We exclude participants from both groups for:\n\n* Skin diseases\n* Current tobacco use\n* Diagnosed or suspected hepatic or metabolic disease including diabetes\n* Diagnosed with depression or other mood-related disorders, asthma, chronic obstructive pulmonary disease, cystic fibrosis, or pulmonary fibrosis\n* Use of prescribed NSAIDs, statins or other cholesterol-lowering medication, antihypertensive medication, carbonic anhydrase inhibitors, corticosteroids, thyroid medications, antidepressants or mood stabilizers, diuretics, phenothiazines, or benzodiazepines\n* History of preeclampsia or gestational hypertension,\n* History or family history of panic disorder,\n* Currently pregnant\n* Body mass index \\\u003C18.5 kg\u002Fm2,\n* Allergy to materials used during the experiment (e.g. latex), known allergies to study drugs.\n* History of heavy alcohol use\u002Fbinge drinking,\n* Have planned procedures with radiological contrast,\n* Have a major dental procedure\u002Fsurgery coming up, such as a dental extraction\n* Anatomy of the middle cerebral artery or internal carotid artery that prevents adequate ultrasonography and\u002For and data collection","50 Years",{"count":51,"type":22},84,[53],"PHASE1","Gestational Diabetes Mellitus (GDM) currently affects approximately 14% of all pregnancies worldwide. Importantly, the health-related consequences of GDM extend well beyond pregnancy, such that women with a history of GDM have a 40% increased risk of cerebrovascular diseases and a 67% increased risk of dementia, compared to women with a history of uncomplicated pregnancy. Women with a history of GDM have impaired skin microvascular function, compared with women with a history of uncomplicated pregnancy. Therefore, it's likely that GDM results in impaired brain blood vessel function, yet there is little-to-no information regarding the effects of GDM on brain blood vessel health and function after pregnancy.\n\nTherefore, the purpose of the study is to evaluate the effects of GDM on brain blood flow and brain blood vessel function in healthy women with either a history of GDM or uncomplicated pregnancy.\n\nIn this study, the investigators will use two different types of ultrasound to non-invasively measure brain blood flow. Brain blood vessel function will be evaluated by examining the brain blood flow responses to increases in carbon dioxide (the increases in carbon dioxide are similar to what is experienced during a breath hold). Additionally, the investigators will compare the brain blood flow results to skin microvascular function to explore potential mechanisms behind possible impairments in brain blood vessel function. Skin microvascular function will be assessed using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) on dime sized areas of the forearm. Finally, for screening purposes and to further explore potential mechanisms behind any potential impairments in brain blood vessel function, the investigators will perform blood draws to determine the metabolic health of the participants and to analyze for substances that influence blood vessel function.",[56,57,58],"Gestational Diabetes Mellitus (GDM)","Postpartum Women","Uncomplicated Pregnancy",[60,61,62,63],"Gestational Diabetes","Brain Blood Flow","Pregnancy","Postpartum","2025-12-08",{"date":66,"type":34},"2025-12-16",{"date":68,"type":34},"2025-08-22",{"date":70,"type":22},"2028-04-15",{"name":40,"class":41},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":42},"100558169","early-phase-1-role-of-et-1-physical-activity-and-sedentary-behavior-in-microvascular-dysfunction-following-gdm-100558169","NCT06547619","Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM","INCLUSION CRITERIA\n\n* history of pregnancy within 5 years of the study visit\n* had healthy pregnancy OR had gestational diabetes diagnosed by their obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes.\n\nEXCLUSION CRITERIA\n\n* skin diseases,\n* current tobacco or electronic cigarette\u002Fvape pen use,\n* diagnosed or suspected hepatic or metabolic disease including diabetes,\n* statin or other cholesterol-lowering medication,\n* current antihypertensive medication,\n* history of preeclampsia or gestational hypertension\n* current hypertension,\n* current pregnancy,\n* body mass index \\\u003C18.5 kg\u002Fm2,\n* allergy to materials used during the experiment.(e.g. latex), known allergies to study drugs.",{"count":21,"type":22},[25],"Women with a history of gestational diabetes mellitus (GDM) are at a 2-fold greater risk for the development of overt cardiovascular disease (CVD) following the effected pregnancy. While subsequent development of type II diabetes elevates this risk, prior GDM is an independent risk factor for CVD morbidity, particularly, within the first decade postpartum. GDM is associated with impaired endothelial function during pregnancy and decrements in macro- and microvascular function persist postpartum, despite the remission of insulin resistance following delivery. Collectively, while the association between GDM and elevated lifetime CVD risk is clear, and available evidence demonstrates a link between GDM and vascular dysfunction in the decade following pregnancy, the mechanisms mediating this persistent dysfunction remain unexamined.\n\nThe purpose of this investigation is to examine the role of endothelin-1, a potent vasoconstrictor, in aberrant microvascular function in otherwise healthy women with a history of GDM and to identify whether this mechanism is influenced by physical activity and sedentary behavior.",[60,82,83],"Endothelial Dysfunction","Physical Inactivity",{"date":85,"type":34},"2025-12-09",{"date":87,"type":34},"2024-10-01",{"date":89,"type":22},"2027-05",{"name":40,"class":41},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":42},"100529029","early-phase-1-daily-aspirin-treatment-after-preeclampsia-100529029","NCT06168461","Daily Aspirin Treatment After Preeclampsia","Aspirin for the Treatment of Vascular Dysfunction After Preeclampsia","Inclusion Criteria:\n\n* had preeclampsia in the past 5 years,\n* 18 years or older\n\nExclusion criteria:\n\n* current daily aspirin use,\n* skin diseases,\n* current tobacco or nicotine use (including vaping),\n* diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m2,\n* statin or other cholesterol-lowering medication,\n* current antihypertensive medication,\n* history of hypertension prior to pregnancy,\n* history of gestational diabetes,\n* currently pregnancy,\n* body mass index \\\u003C18.5 kg\u002Fm2,\n* allergy to materials used during the experiment.(e.g. latex),\n* known allergies to study drugs,\n* bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).",{"count":21,"type":22},[25],"Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.",[28],[103],"preeclampsia",{"date":105,"type":34},"2025-12-15",{"date":107,"type":34},"2023-11-01",{"date":109,"type":22},"2026-06",{"name":40,"class":41},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":16,"sex":117,"minAge":18,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":42},"100528349","early-phase-1-sex-differences-in-the-vascular-effects-of-e-cigarette-use-100528349","NCT06159608","Sex Differences in the Vascular Effects of E-cigarette Use","Inclusion Criteria:\n\n* 18-24 years old\n* one of the following:\n\n  1. have no history of e-cigarette use\n  2. be a current e-cigarette user who has been using e-cigarettes for 6 months or longer\n\nExclusion Criteria:\n\n* history of cardiovascular, metabolic, and\u002For skin diseases\n* body mass index \\>30 kg\u002Fm2\n* blood pressure ≥140 systolic and\u002For ≥ 90 diastolic\n* current or history of tobacco cigarette use\n* current antihypertensive or cholesterol-lowering medication\n* current use of cannabis, marijuana, and\u002For other illegal substances\n* current use of stimulant drugs\n* currently pregnant or breastfeeding\n* allergy to materials used during the experiment (e.g. latex),\n* known allergy to study drugs\n* healthy control subjects will also be excluded if they have ever used e-cigarettes in the past","ALL","24 Years",{"count":120,"type":22},80,[25],"The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as \"vaping\" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored.\n\nIn this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a dime-sized area of the skin in otherwise healthy young (18-24yrs) chronic e-cigarette users. Local heating of the skin at the microdialysis sites is used to explore differences in mechanisms governing microvascular control. As a compliment to these measurements, we also draw blood from the subjects to measure circulating factors that may contribute to cardiovascular health and examine markers of inflammatory activation. We will also collect urine from female participants to measure estradiol.",[124],"E-cigarette Use",{"date":105,"type":34},{"date":127,"type":34},"2023-12-02",{"date":129,"type":22},"2026-12",{"name":40,"class":41},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":42},"100511315","early-phase-1-sensitivity-of-angiotensin-ii-type-ii-receptors-in-women-following-preeclampsia-100511315","NCT05937841","Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia","Inclusion Criteria:\n\n* women who had preeclampsia and women who did not have preeclampsia\n* 12 weeks to 5 years postpartum\n* 18-45 years old\n\nExclusion Criteria:\n\n* history of hypertension or metabolic disease before pregnancy\n* history of gestational diabetes\n* skin diseases\n* current tobacco use\n* current antihypertensive medication\n* statin or other cholesterol-lowering medication\n* currently pregnant or planning to become pregnant\n* body mass index less than 18.5 kg\u002Fm2\n* allergy to materials used during the experiment.(e.g. latex),\n* known allergy to study drugs",{"count":138,"type":22},30,[25],"Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women.\n\nThe purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. This will help increase understanding of the mechanisms of angiotensin II receptors in these women, and how activation of these receptors may restore microvascular function.\n\nIn this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.",[29],"2025-08-19",{"date":144,"type":34},"2025-08-24",{"date":146,"type":34},"2023-06-28",{"date":148,"type":22},"2026-06-01",{"name":40,"class":41},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":42},"100489504","early-phase-1-prenatal-aspirin-and-postpartum-vascular-function-100489504","NCT05653973","Prenatal Aspirin and Postpartum Vascular Function","Protective Mechanisms of Prenatal Aspirin Therapy on Maternal Vascular Dysfunction Following Preeclampsia","Inclusion:\n\n* 18 years or older,\n* 12 weeks to 5 years postpartum\n* and one of the following:\n\n  1. women who had a normal pregnancy and did not use low does aspirin (LDA) during pregnancy,\n  2. women who had a normal pregnancy and used LDA during pregnancy,\n  3. women who had preeclampsia and did not use LDA during pregnancy,\n  4. women who had preeclampsia and used LDA during pregnancy.\n\nExclusion:\n\n* current daily aspirin use,\n* skin diseases,\n* current tobacco use,\n* diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m2,\n* statin or other cholesterol-lowering medication,\n* current antihypertensive medication,\n* history of hypertension prior to pregnancy,\n* history of gestational diabetes,\n* current pregnancy,\n* body mass index \\\u003C18.5 kg\u002Fm2,\n* allergy to materials used during the experiment.(e.g. latex),\n* known allergies to study drugs.",{"count":158,"type":22},60,[25],"Preeclampsia is a pregnancy disorder affecting \\~5-10% of pregnancies in the United States. Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. Low dose aspirin (LDA; 75-150mg\u002Fdaily) is currently the most effective and clinically accepted therapy for reducing preeclampsia prevalence in women at high risk for developing the syndrome. The purpose of this study is to interrogate the mechanisms by which LDA therapy mitigates persistent vascular dysfunction in postpartum women who have had preeclampsia.\n\nIn this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) they examine the blood vessels in a dime-sized area of the skin in women who have had a history of preeclampsia. As a compliment to these measurements, they also draw blood from the subjects and isolate the inflammatory cells.",[28,162],"Microvascular Function","2025-05-27",{"date":165,"type":34},"2025-05-31",{"date":167,"type":34},"2023-01-03",{"date":169,"type":22},"2027-07-30",{"name":40,"class":41},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":42},"100512002","early-phase-1-oxidative-stress-in-microvascular-dysfunction-following-gestational-diabetes-100512002","NCT05946785","Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes","Role of Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes","INCLUSION CRITERIA:\n\n* female sex\n* 18 -50 years old\n* pregnancy history within 5 years of the study visit\n* had gestational diabetes diagnosed by their obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes\n* or without a history of gestational diabetes\n\nEXCLUSION CRITERIA:\n\n* skin diseases\n* current tobacco\u002Fe-cigarette use\n* diagnosed or suspected hepatic or metabolic disease including diabetes\n* statin or other cholesterol-lowering medication\n* current antihypertensive medication\n* history of preeclampsia or gestational hypertension\n* current pregnancy\n* body mass index \\\u003C18.5 kg\u002Fm2\n* allergy to materials used during the experiment.(e.g. latex), known allergies to study drugs.",{"count":179,"type":22},28,[25],"The purpose of this investigation is to examine the role of oxidative stress in aberrant microvascular function in otherwise healthy women with a history of GDM.",[60,183],"Vascular Endothelial Function",[185,186,187],"gestational diabetes","postpartum","vascular","2025-05-07",{"date":190,"type":34},"2025-05-13",{"date":192,"type":34},"2023-07-01",{"date":194,"type":22},"2027-06-01",{"name":40,"class":41},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":42},"100512003","early-phase-1-role-of-nadph-oxidase-in-microvascular-dysfunction-following-gdm-100512003","NCT05946798","Role of NADPH Oxidase in Microvascular Dysfunction Following GDM","INCLUSION CRITERIA:\n\n* 18 years or older\n* pregnant within 5 years of the study visit\n* had gestational diabetes diagnosed by their obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes.\n* or without a history of gestational diabetes\n\nEXCLUSION CRITERIA:\n\n* skin diseases\n* current tobacco or electronic cigarette\u002Fvape pen use,\n* diagnosed or suspected hepatic or metabolic disease including diabetes,\n* statin or other cholesterol-lowering medication,\n* current antihypertensive medication,\n* history of preeclampsia or gestational hypertension,\n* current pregnancy,\n* body mass index \\\u003C18.5 kg\u002Fm2,\n* allergy to materials used during the experiment.(e.g. latex),\n* known allergies to study drugs",{"count":21,"type":22},[25],"The purpose of this investigation is to examine NADPH oxidase as a source of reactive oxygen species contributing to aberrant microvascular function in otherwise healthy women with a history of GDM.",[60,206,183],"Oxidative Stress",[185,186,187],{"date":190,"type":34},{"date":210,"type":34},"2023-08-30",{"date":212,"type":22},"2028-06-01",{"name":40,"class":41},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":42},"100509757","early-phase-1-metformin-for-the-treatment-of-microvascular-dysfunction-after-gestational-diabetes-100509757","NCT05917587","Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes","Inclusion Criteria:\n\n* ≥12 weeks and ≤5 years postpartum\n* history of GDM or healthy pregnancy\n\nExclusion Criteria:\n\n* prediabetes or diabetes (HbA1c ≥5.7%)\n* current tobacco use\n* cardiovascular or metabolic disease\n* cardiovascular or metabolic medication\n* history of hypertension during pregnancy\n* current pregnancy",{"count":138,"type":22},[25],"The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.",[60],[185,186,187],{"date":190,"type":34},{"date":227,"type":34},"2024-09-11",{"date":229,"type":22},"2028-06-30",{"name":40,"class":41},""]